X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Cresemba (isavuconazonium sulfate) is the prodrug of isavuconazole which is an azole antifungal indicated for the treatment of invasive aspergillosis and invasive mucormycosis.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
Under the licensing agreement, Knight will focus on the Cresemba (isavuconazole sulfate) to commercialize in Latin America. It is an approved azole antifungal product indicated for the treatment of adult patients with invasive aspergillosis.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Knight Therapeutics
Deal Size: Undisclosed Upfront Cash: $11.2 million
Deal Type: Licensing Agreement January 19, 2024
Details:
FDA approves expanded use of Cresemba® (isavuconazonium sulfate), an ergosterol inhibitor, in pediatric patients 1 year of age and older with invasive aspergillosis and invasive mucormycosis.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2023
Details:
Pfizer has the right to manufacture Cresemba, an intravenous, oral azole antifungal, and exclusively commercialize the drug in Europe, the Asia Pacific and China regions. Isavuconazonium sulfate has been approved in 73 countries for invasive aspergillosis and mucormycosis.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $1,095.4 million Upfront Cash: $72.3 million
Deal Type: Licensing Agreement November 20, 2023
Details:
CRESEMBA (isavuconazonium sulfate) is a prodrug of isavuconazole, an azole antifungal drug. CRESEMBA is indicated for patients 18 years of age and older for the treatment of invasive aspergillosis and invasive mucormycosis.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
Pfizer has the right to manufacture Cresemba, an intravenous, oral azole antifungal, and exclusively commercialize the drug in Europe, the Asia Pacific and China regions. Isavuconazonium sulfate has been approved in 73 countries for invasive aspergillosis and mucormycosis.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $1,094.2 million Upfront Cash: $72.3 million
Deal Type: Licensing Agreement June 08, 2023
Details:
Under the terms of the initial agreement, Asahi Kasei Pharma received exclusive rights to develop and commercialize Basilea’s antifungal Cresemba (isavuconazole), an intravenous and oral azole antifungal, in Japan.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Asahi Kasei Pharma
Deal Size: $72.3 million Upfront Cash: $7.5 million
Deal Type: Licensing Agreement March 23, 2023
Details:
Isavuconazonium sulfate is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba. The license agreement between Basilea and Pfizer for Cresemba covers Europe as well as countries in the Asia Pacific region and China.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $1,068.5 million Upfront Cash: $72.3 million
Deal Type: Licensing Agreement February 07, 2023
Details:
Isavuconazonium sulfate is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba. Cresemba is approved in the United States for patients 18 years of age and older for the treatment of invasive aspergillosis and invasive mucormycosis.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $511.6 million Upfront Cash: $69.3 million
Deal Type: Licensing Agreement January 09, 2023
Details:
Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba. Cresemba is approved in 69 countries to date and is currently marketed in 59 countries.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2022
Details:
Intravenous use of Cresemba (Isavuconazole) approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis following previous approval of oral dosage form.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
Isavuconazole is an intravenous and oral azole antifungal, commercialized under the trade name Cresemba. Basilea has entered into several license and distribution agreements for isavuconazole, covering the United States, Europe, China, Japan, Latin America, Asia-Pacific.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $1068.5 million Upfront Cash: $72.3 million
Deal Type: Licensing Agreement June 17, 2022
Details:
With this authorization, oral Cresemba is now approved in China for the treatment of adult patients with invasive mucormycosis. The granting of the Drug Approval License triggered a milestone payment from Pfizer to Basilea.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $729.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 21, 2021
Details:
Under the terms of agreement, Pfizer will have the right to manufacture isavuconazole and to commercialize the drug in Europe (excluding the Nordics), Russia, Turkey and Israel as well as China (including Hong Kong and Macao) and sixteen countries in the Asia Pacific region.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $610.0 million Upfront Cash: $76.5 million
Deal Type: Licensing Agreement December 08, 2021
Details:
Under the terms of the agreement, Asahi Kasei Pharma was granted an exclusive license to develop and commercialize isavuconazole in Japan.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Asahi Kasei Pharma
Deal Size: $72.3 million Upfront Cash: $7.5 million
Deal Type: Partnership September 30, 2021
Details:
The phase 3, multi-center, open-label study enrolled 103 patients and was assessing the safety and efficacy of intravenously or orally administered isavuconazole for the treatment of adult Japanese patients suffering from deep-seated mycoses.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Asahi Kasei Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2021
Details:
The phase 3 study enrolled 103 patients and is assessing the safety and efficacy of isavuconazole in adult Japanese patients suffering from deep-seated mycoses, including invasive aspergillosis and mucormycosis.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Basilea Pharmaceutica
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
Center for Drug Evaluation at the National Medical Products Administration of China has accepted Basilea's marketing authorization application for isavuconazole (Cresemba®) to treat patients with mucormycosis, which was submitted by Basilea’s license partner Pfizer Inc.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2020
Details:
Basilea Pharmaceutica reported that its license partner, Pfizer has launched the antifungal Cresemba® (isavuconazole) in Taiwan.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $1068.5 million Upfront Cash: $72.3 million
Deal Type: Licensing Agreement July 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
